DOCUMENT
10.1038_s41392-020-0177-z.pdf (1.41 MB)
DOCUMENT
supp_41392_2020_177_MOESM1_ESM.docx (2.52 MB)
1/0
Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application
journal contribution
submitted on 2024-05-14, 05:26 and posted on 2024-05-14, 05:27 authored by Afsaneh Sadremomtaz, Ameena M. Ali, Foroozan Jouyandeh, Saeed Balalaie, Razieh Navari, Sylvain Broussy, Kamran Mansouri, Matthew R. Groves, S. Mohsen AsghariTumor angiogenesis is regulated by the binding of VEGF to receptors (VEGFRs). The major mediator of tumor angiogenesis is VEGFA, more commonly referred to as VEGF. VEGFR1 binds VEGF with higher affinity (10 times) than VEGFR2.1 However, the role of the VEGFR1 in VEGF-mediated angiogenesis remains a mystery.
Other Information
Published in: Signal Transduction and Targeted Therapy
License: https://creativecommons.org/licenses/by/4.0
See article on publisher's website: https://dx.doi.org/10.1038/s41392-020-0177-z
History
Language
- English
Publisher
Springer NaturePublication Year
- 2020
License statement
This Item is licensed under the Creative Commons Attribution 4.0 International License.Institution affiliated with
- Hamad Bin Khalifa University
- Qatar Biomedical Research Institute - HBKU
